Video claim watch

New Data Released on Weight-Loss Drug Retatrutide

A large morning-news audience received a compressed explanation of new retatrutide data, making it useful for tracking public interpretation of trial results.

Good Morning America channel2:55 runtime51K views when checked

Published May 21, 2026. Metadata checked Jul 12, 2026.

Watch on YouTube

Connected research

Compounds discussed

Retatrutide Retatrutide is an investigational triple-agonist peptide (GLP-1, GIP, and glucagon receptor agonist) developed by Eli Lilly that showed significant weight loss in Phase 2 clinical trials. It is not FDA-approved for any indication. The peptide has received high online attention from biohacking and fitness communities, requiring careful separation of clinical trial data from social media claims.

Source check

Primary and peer-reviewed records

Retatrutide for Obesity: A Phase 2 Trial

New England Journal of Medicine · Peer reviewed · 2023-06-26 · accessed 2026-07-01

Phase 2 randomized trial of retatrutide (LY3437943), a triple GLP-1/GIP/glucagon receptor agonist, showing dose-dependent weight loss up to 17.5% at 48 weeks in adults with obesity.

TRIUMPH Phase 3 Trial Program for Retatrutide: ClinicalTrials.gov

ClinicalTrials.gov / U.S. National Library of Medicine · Primary regulatory · 2023-07-01 · accessed 2026-07-01

ClinicalTrials.gov registry entry for the TRIUMPH Phase 3 trial program evaluating retatrutide for obesity, sponsored by Eli Lilly. Retatrutide is not FDA-approved for any indication.